b. 
c . 
d. 
e . 
f . 
g- 
( PTT) , and Pro 
control to prevent pregnancy for the duration of the study. Men 
will be advised to use barrier protection for the duration of the 
study. 
4. Parents must possess the ability to give informed consent and 
express a willingness to meet all the expected requirements of the 
protocol for the duration of the study. (Appendix L) . 
5. Adequate baseline organ function as assessed by the following 
laboratory values before surgery: 
a. Adequate renal function with serum creatinine of < 1.5 
mg/dl or creatinine clearance > 45 mL/min/m 2 . 
Platelet count > 100,000 platelets/mm 3 . 
Absolute neutrophil count > 1000/mm 3 . 
Hemoglobin >8.5 mg/dL. 
Normal Partial Thromboplastin Time 
Thrombin Time (PT) . 
Bilirubin < 2.5 mg/dL, SGOT and SGPT < 4x normal. 
Patients with a performance status of < ECOG 3 will be 
excluded from the study. (See Appendix H) . 
6. Patients admitted for study under this protocol will be 
registered with the principal investigator at Childrens Hospital 
Los Angeles. 
B. Exclusion Criteria: 
Patients with the following conditions will be excluded from 
the study : 
1. Acute infection. Active infection is defined as any 
acute viral, bacterial or fungal infection which requires 
specific therapy. 
2. Neurological deterioration. Patients with an increased 
ICP who require prompt reduction of ICP will be excluded. 
HIV positive patients. 
Pregnant patients. 
Multiple tumors. 
Post-surgical cavity in continuity with subarachnoid 
cistern or ventricular space. 
Prior history of brachytherapy or stereotaxic 
radiotherapy. 
Tumor greater than 7 cm. in any diameter. 
II. Clinical Evaluation 
A. Preliminary Evaluation and Screening 
The following evaluation must be completed before patient 
entry into the study. 
1. Before a patient can be entered into this study, the 
investigators must receive information from the referring 
physician (s) detailing the clinical history, general 
laboratory results, specific neurologic and radiologic 
evaluations, their diagnosis, and all previous therapies 
(Appendix I: Patient Screening Form). 
2. Data substantiating the histopathological diagnosis must 
be received and reviewed by the reference pathologist 
(Dr. Floyd Gilles, CHLA) prior to participation in the 
study. If no recent tissue diagnosis is available, the 
nature of the space occupying lesion (e.g. tumor vs. 
radiation necrosis) will be determined by a stereotaxic 
8 
[64] 
Recombinant DNA Research, Volume 18 
